Asset Details
Do you wish to reserve the book?
Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double-masked open-label clinical trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double-masked open-label clinical trial
Do you wish to request the book?
Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double-masked open-label clinical trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double-masked open-label clinical trial
2015
Overview
Background/aims To assess the efficacy and safety of oral azithromycin compared with oral doxycycline in patients with meibomian gland dysfunction (MGD) who had failed to respond to prior conservative management. Methods 110 patients (>12 years old) with MGD were randomly assigned to receive either oral 5-day azithromycin (500 mg on day 1 and then 250 mg/day) or 1-month doxycycline (200 mg/day). They also continued eyelid warming/cleaning and artificial tears. A score comprising five symptoms and seven signs (primary outcome) was recorded prior to treatment and at 1 week, and 1 and 2 months after treatment. Total score was the sum of both scores at each follow-up. Side effects were recorded and overall clinical improvement was categorised as excellent, good, fair or poor based on the percentage of change in the total score. Results Symptoms and signs improved significantly in both groups (p=0.001). While improvement of symptoms was not different between the groups, bulbar conjunctival redness (p=0.004) and ocular surface staining (p=0.01) were significantly better in the azithromycin group. The azithromycin group showed a significantly better overall clinical response (p=0.01). Mild gastrointestinal side effects were not significantly different between the groups except for the second visit, when the doxycycline group had significantly more side effects (p=0.002). Conclusions Although both oral azithromycin and doxycycline improved the symptoms of MGD, 5-day oral azithromycin is recommended for its better effect on improving the signs, better overall clinical response and shorter duration of treatment. Trial registration number NCT01783860.
Publisher
BMJ Publishing Group LTD
Subject
/ Adult
/ Anti-Bacterial Agents - adverse effects
/ Anti-Bacterial Agents - therapeutic use
/ Azithromycin - adverse effects
/ Azithromycin - therapeutic use
/ Doxycycline - adverse effects
/ Doxycycline - therapeutic use
/ Eyelid Diseases - drug therapy
/ Eyelid Diseases - physiopathology
/ Female
/ Humans
/ Lubricant Eye Drops - administration & dosage
/ Male
/ Meibomian Glands - drug effects
/ Meibomian Glands - pathology
/ Signs
/ Studies
